Evaluation of Safety, Tolerability, and Immunological Response of ASP2390 in Adults with House Dust Mite Allergy

The primary objective of this study is to evaluate the **safety** and **tolerability** of ASP2390 in adult subjects with an **allergy to house dust mites**. This is clinically relevant as it aims to determine the potential adverse effects and overall acceptability of ASP2390, which could inform its future use in managing this common allergic condition. The study also seeks to assess the **immunological response** to ASP2390, which is crucial for understanding its potential efficacy in modulating the immune system's reaction to house dust mites.

The clinical trial focuses on participants with **allergy to house dust mites**. The study population includes both male and female subjects, encompassing an age range that includes both children and adolescents. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that are not explicitly detailed in the available data. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial does not provide further information on key inclusion or exclusion criteria.

The clinical trial is designed to evaluate the **safety**, tolerability, and immunological response of ASP2390 in adult subjects with an **allergy to house dust mites**. This study is a Phase 1 trial, which is typically the first stage in testing a new treatment in humans. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from January 1, 2020, to December 22, 2026, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following the screening, participants will attend regular follow-up visits, which are scheduled to monitor their health status, assess the treatment's effects, and collect necessary data. These visits are integral to maintaining participant safety and evaluating the trial's primary and secondary endpoints. The study will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed.

The expected length of participant involvement in the trial is determined by the study's protocol, which outlines the schedule of visits and assessments. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with the study protocol, or withdraw consent. Such conditions are in place to prioritize participant safety and maintain the integrity of the trial data. The trial's design and procedures are structured to ensure a thorough evaluation of ASP2390's potential benefits and risks in treating house dust mite allergy.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess the efficacy of the investigational treatment over a specified period. The trial is categorized as a Phase 1 study, which typically focuses on evaluating the safety, tolerability, and pharmacokinetics of the treatment in a small group of participants. The estimated recruitment start date for the trial was January 1, 2020, and the estimated end date is December 22, 2026. The primary and secondary endpoints, as well as specific methods for measuring efficacy, are not detailed in the available data. The trial will proceed according to the established protocol, adhering to regulatory and ethical standards to ensure the integrity and reliability of the collected data.